<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41875">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561234</url>
  </required_header>
  <id_info>
    <org_study_id>CAEB1102-100B</org_study_id>
    <nct_id>NCT02561234</nct_id>
  </id_info>
  <brief_title>A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeglea Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeglea Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first-in-human study of the safety of increasing dose levels of AEB1102 in
      patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in
      blood, the effects of AEB1102 on blood amino acid levels and tumor growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase I multiple dose, dose escalation study utilizing a classic 3+3 design.
      Sequential cohorts of patients will receive AEB1102 IV weekly at one of a series of
      increasing dose levels. Dose escalation will be dependent on the frequency of specific
      dose-limiting toxicities in the prior cohort of patients. The study will determine the
      maximum tolerated dose (MTD) of AEB1102, evaluate the safety profile of the compound, assess
      the pharmacokinetic profile of AEB1102, determine the effect of AEB1102 on blood arginine
      levels and evaluate the anti-tumor activity of AEB1102.

      Following the determination of the MTD, additional cohorts of ~20 patients each with a
      specific solid tumor subtype will be enrolled and treated with AEB1102 at the MTD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>4 weeks</time_frame>
    <description>the dose level at which no more than 1/6 patients experiences dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety profile (changes in physical exam, laboratory measures, reported adverse events)</measure>
    <time_frame>4 weeks +</time_frame>
    <description>changes in physical exam, laboratory measures, reported adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>AEB1102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AEB1102 (Co-ArgI-PEG) will be administered IV weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-ArgI-PEG</intervention_name>
    <description>modified human arginase I</description>
    <arm_group_label>AEB1102</arm_group_label>
    <other_name>AEB1102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has an advanced solid tumor and has failed standard therapy-is a candidate for Phase
             1 treatment

          -  has adequate organ function: Hgb ≥10, ANC ≥ 1.5, plt ≥ 100,000; AST/ALT &lt; 2.5x ULN,
             bilirubin &lt; 2.0; serum creatinine ≤ 1.5x ULN

          -  ECOG score 0-2

          -  willing to use physician approved birth control method

        Exclusion Criteria:

          -  has primary CNS malignancy

          -  history of untreated brain mets or leptomeningeal disease or spinal cord compression

          -  effects of prior anticancer therapy recovered to grade &lt; 2

          -  known HIV

          -  active infection

          -  major surgery within 2 weeks

          -  history of another malignancy within 2 years prior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Rojas-Caro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aeglea Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon Lewis Berlin</last_name>
    <phone>1-855-509-9921</phone>
    <email>clinical@aegleabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Eckhardt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>START</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Rasco, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 7, 2016</lastchanged_date>
  <firstreceived_date>August 25, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
